683 related articles for article (PubMed ID: 31967304)
21. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve.
Friis Wang N; Bogstad JW; Pors SE; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
Hum Reprod; 2023 Apr; 38(4):716-725. PubMed ID: 36721920
[TBL] [Abstract][Full Text] [Related]
22. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
23. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
24. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients.
Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O
Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834
[TBL] [Abstract][Full Text] [Related]
25. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
26. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial.
Saunders H; Khan C; D'Hooghe T; Magnúsdóttir TB; Klingmann I; Hrafnsdóttir S;
Hum Reprod; 2020 Feb; 35(2):355-363. PubMed ID: 32074281
[TBL] [Abstract][Full Text] [Related]
28. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
[TBL] [Abstract][Full Text] [Related]
29. Serum progesterone is lower in ovarian stimulation with highly purified HMG compared to recombinant FSH owing to a different regulation of follicular steroidogenesis: a randomized controlled trial.
Bosch E; Alamá P; Romero JL; Marí M; Labarta E; Pellicer A
Hum Reprod; 2024 Feb; 39(2):393-402. PubMed ID: 38037188
[TBL] [Abstract][Full Text] [Related]
30. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
32. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization.
Baker VL; Jones CA; Doody K; Foulk R; Yee B; Adamson GD; Cometti B; DeVane G; Hubert G; Trevisan S; Hoehler F; Jones C; Soules M
Hum Reprod; 2014 Oct; 29(10):2212-20. PubMed ID: 25100106
[TBL] [Abstract][Full Text] [Related]
33. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
[TBL] [Abstract][Full Text] [Related]
34. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
35. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
[TBL] [Abstract][Full Text] [Related]
37. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.
Beguería R; García D; Vassena R; Rodríguez A
Hum Reprod; 2019 May; 34(5):872-880. PubMed ID: 30927417
[TBL] [Abstract][Full Text] [Related]
38. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles.
Lawrenz B; Beligotti F; Engelmann N; Gates D; Fatemi HM
Hum Reprod; 2016 Nov; 31(11):2554-2560. PubMed ID: 27619773
[TBL] [Abstract][Full Text] [Related]
39. Investigation of luteal HCG supplementation in GnRH-agonist-triggered fresh embryo transfer cycles: a randomized controlled trial.
Svenstrup L; Möller S; Fedder J; Pedersen DE; Erb K; Andersen CY; Humaidan P
Reprod Biomed Online; 2024 May; 48(5):103415. PubMed ID: 38452605
[TBL] [Abstract][Full Text] [Related]
40. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
